Study of CM512 Injection in Subjects With Moderate-to-severe Asthma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of CM512 Injection in Subjects With Moderate-to-severe Asthma — Stella

Recruiting

Back to Asthma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

The First Clinical Hospital of Guangzhou Medical University, Guangzhou, Guangdong

Key details

Phase

Safety & dosing

Sponsor

Keymed Biosciences Co.Ltd

Enrollment target

~200 participants

Started

August 2025

Primary completion

July 2027

Age range

18 Years – 75 Years

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov